Related Experiment Videos
Dideoxyinosine for chronic hepatitis B infection
A P Catterall1, G J Moyle, E A Hopes
1Department of Gastroenterology, Charing Cross Hospital, London, U.K.
Journal of Medical Virology
|August 1, 1992
Summary
Dideoxyinosine (DDI) showed no significant antiviral effect on hepatitis B virus (HBV) replication in patients coinfected with human immunodeficiency virus (HIV). While generally well-tolerated, DDI did not substantially alter HBV DNA levels in most participants.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Coinfection with human immunodeficiency virus (HIV) complicates management and treatment strategies.
- Dideoxyinosine (DDI) is an antiretroviral nucleoside analog with potential activity against viral replication.
Purpose of the Study:
- To evaluate the efficacy of dideoxyinosine (DDI) in suppressing hepatitis B virus (HBV) replication.
- To assess the safety and tolerability of DDI in patients coinfected with HIV and HBV.
Main Methods:
- A cohort of six patients coinfected with HIV and HBV received dideoxyinosine (DDI) therapy.
- Hepatitis B virus (HBV) DNA levels were monitored during the treatment period.
- Clinical outcomes and side effects were recorded.
Main Results:
- One patient achieved transient HBV DNA suppression.
- Five patients showed no significant change in HBV DNA levels during DDI therapy.
- DDI was generally well-tolerated, with diarrhea being the most common side effect.
Conclusions:
- Dideoxyinosine (DDI) demonstrates limited antiviral activity against chronic hepatitis B virus (HBV) infection in HIV-coinfected individuals.
- Further research may be needed to explore alternative therapeutic strategies for this patient population.